SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
MusclePharm Corporation (MSLP) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 11/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MSLP
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.31
Book Value / Share$0.00
Revenue / Share$1.22
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$-18.02 |
$67.06M |
$-26.29M |
-39.2% |
| 2013 |
$-2.46 |
$110.88M |
$-17.72M |
-16% |
| 2014 |
$-1.25 |
$177.39M |
$-13.83M |
-7.8% |
| 2015 |
$-3.81 |
$166.86M |
$-51.86M |
-31.1% |
| 2016 |
$-0.26 |
$132.5M |
$-3.48M |
-2.6% |
| 2017 |
$-0.79 |
$102.16M |
$-10.97M |
-10.7% |
| 2018 |
$-0.72 |
$88.11M |
$-10.76M |
-12.2% |
| 2019 |
$-0.92 |
$79.67M |
$-18.93M |
-23.8% |
| 2020 |
$0.08 |
$64.44M |
$3.19M |
4.9% |
| 2021 |
$-0.31 |
$50.04M |
$-12.88M |
-25.7% |
